NeoGenomics, Inc. (NEO)
NASDAQ • Healthcare
Last close at September 18, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, NeoGenomics, Inc. keeps $1 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Oct 27
in 37 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
NeoGenomics beat expectations on revenue in the second fiscal quarter of 2026, reported July 28, 2026, with revenue up 11.2% to about $201.7 million (from roughly $181.3 million a year ago) as its cancer-focused testing and research services business continued to expand across Clinical Services and Pharma Services. On the consensus comparison, revenue of $201.7 million topped the $196.9 million estimate, +2.4%. Gross profit came in at about $91.9 million, translating to a gross margin of roughly 46%, while profitability remained negative at the operating line with operating income of about -$9.8 million and an operating margin of around -5%. Adjusted EPS was $0.05, up from $0.03 a year ago. The company generated operating cash flow of about $20.0 million during the quarter and repurchased roughly $22.7 million of stock. For the next period, consensus calls for EPS of $0.06 on revenue of $205.9 million.
About NeoGenomics, Inc.
NeoGenomics, Inc. provides cancer-focused diagnostic testing and research services within healthcare, operating in the medical diagnostics and research business. Listed on the NASDAQ as NEO, it generated $727.3 million of revenue in FY2025 through laboratory testing for patient care and services that support drug-development programs.
Today's Snapshot
NEO ended the day slightly higher at 19.91, in line with a flat sector. Volume was roughly twice its usual level. Simply Wall St. said NeoGenomics shares look expensive relative to its current sales.
Trading Volume
Above 10d avg 1.7M
3.6M
vs S&P 500 Today
Inline with Market
+0.02%
Updated: September 18, 2026 at 20:06 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$12.82 - $18.66Buy
- RSI (14)73.90Sell
- Stochastic %K (14, 3, 3)89.36Sell
- MACD Level (12, 26)0.87Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.